IMAX's third-quarter report serves as an important checkpoint for a company experiencing unusually strong box office momentum. In its second quarter of 2026, IMAX delivered revenue of $103 million (up 12% year over year) and adjusted earnings per share of $0.43, both exceeding expectations, helped by the blockbuster opening of The Odyssey. The upcoming quarter captures the heart of that release cycle, making it a key test of whether IMAX can convert theatrical demand into durable, high-margin growth. For investors, the results will signal the strength of the company's dual business model, spanning content-driven revenue and technology system sales, as well as its ability to expand its global theater network. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Heading into the report, analyst consensus forecasts earnings of approximately $0.83 per share on revenue of about $150 million, according to data compiled by MarketBeat. That represents a sharp acceleration from the prior-year quarter, when IMAX posted $0.47 per share and $106.65 million in revenue, implying expected earnings growth of more than 70% and revenue growth of roughly 40%. Other trackers have cited slightly lower figures, underscoring a degree of variability in estimates, but the direction is consistent: a meaningful year-over-year step-up.
Management has reaffirmed full-year 2026 guidance, including roughly $1.4 billion in global box office and a mid-40s adjusted EBITDA margin, a measure of earnings before interest, taxes, depreciation, and amortization. Analysts will be watching whether the company's third-quarter box office performance, particularly from The Odyssey and Dune: Part Three, keeps that target on track. System activity also matters: IMAX installed 38 systems in the second quarter and signed agreements for 36, and investors will look for continued momentum in both installations and new signings.
Sentiment heading into the print has been broadly constructive, reflecting IMAX's strong recent execution. The company has beaten consensus earnings estimates in seven of its last eight quarters, and its shares have climbed alongside enthusiasm for a loaded film slate. Following the second-quarter release in late July, the stock moved higher as results and guidance reinforced the growth narrative. Still, elevated expectations carry risk: with consensus anticipating a near doubling of earnings, any shortfall in box office performance, system signings, or margin delivery could trigger volatility. China exposure remains a swing factor, as the region's box office can meaningfully influence quarterly content revenue.
Beyond the headline numbers, investors should focus on the durability of IMAX's operating leverage. The company's ability to maintain adjusted EBITDA margins in the mid-40s while revenue scales will be a central theme, especially as a higher mix of technology system sales and upgrades tends to carry stronger margins.
Network expansion is another key signal. Installations, new signings, and the size of the system backlog indicate future recurring revenue from maintenance, rentals, and content distribution. Strong signings in the second quarter, including a push into new locations across Japan, Europe, and Asia-Pacific, suggest a healthy pipeline that management will likely update.
Finally, watch the slate. The back half of 2026 is unusually dense with franchise titles, but release-date congestion and local-language performance in markets such as China and India can shift results quarter to quarter. Cost trends, lease incentives paid to exhibitors, and share repurchase activity will also help investors gauge how IMAX balances growth investment with capital returns. None of this constitutes a price forecast, but together these factors frame the risk and reward around the report.
In reviewing opportunities like this one, I frequently rely on Tickeron’s AI Screener to quickly scan for comparable names and evaluate technical and fundamental factors side by side. It helps surface relevant patterns and signals without spending hours on manual work, which keeps my process more efficient when preparing for earnings reports.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMAX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 35 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 74%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMAX as a result. In 56 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
IMAX moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for IMAX entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMAX advanced for three days, in 221 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
IMAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating fairly steady price growth. IMAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.346) is normal, around the industry mean (12.927). P/E Ratio (62.724) is within average values for comparable stocks, (38.855). Projected Growth (PEG Ratio) (0.934) is also within normal values, averaging (2.430). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (7.037) is also within normal values, averaging (2.898).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of projection and sound systems for large screen theaters
Industry MoviesEntertainment